60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
3.110
+0.150 (5.07%)
At close: Feb 27, 2026, 4:00 PM EST
2.890
-0.220 (-7.07%)
After-hours: Feb 27, 2026, 7:21 PM EST
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $528.56K in the quarter ending September 30, 2025, with 256.87% growth. This brings the company's revenue in the last twelve months to $1.36M, up 202.10% year-over-year. In the year 2024, 60 Degrees Pharmaceuticals had annual revenue of $681.35K with 168.70% growth.
Revenue (ttm)
$1.36M
Revenue Growth
+202.10%
P/S Ratio
2.93
Revenue / Employee
$454,982
Employees
3
Market Cap
4.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | 2.55M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSXTP News
- 26 days ago - 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership - GlobeNewsWire
- 6 weeks ago - 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study - GlobeNewsWire
- 5 months ago - 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study - GlobeNewsWire